FX005 / Pacira - LARVOL DELTA

The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy. (PubMed, Curr Med Res Opin) - "Pivotal trials for three approved ATTR-PN treatments, tafamidis (Fx-005), patisiran (APOLLO), and inotersen (NEURO-TTR), were compared in terms of study design, baseline population characteristics, outcome definitions, and baseline risk. An NMA of ATTR-PN treatments was not feasible, given the observed cross-trial heterogeneity. This decision highlights the importance of careful consideration for clinical heterogeneity that may threaten the validity of indirect comparisons."

Clinical • Heterogeneity • Journal